Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2Phase 3 Interventional

Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD

ClinicalTrials.gov ID: NCT05181995

Public ClinicalTrials.gov record NCT05181995. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 50 mg NYX-783 Once Daily Compared to Placebo in Participants With Post-Traumatic Stress Disorder (PTSD)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 50 mg NYX-783 Once Daily Compared to Placebo in Participants with Post-Traumatic Stress Disorder (PTSD)

Study identification

NCT ID
NCT05181995
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
Aptinyx
Industry
Enrollment
121 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 13, 2021 (Actual)
Primary completion
Mar 30, 2023 (Actual)
Completion
Mar 30, 2023 (Actual)
Last update posted
Apr 7, 2023

2021 – 2023

United States locations

U.S. sites
37
U.S. states
15
U.S. cities
36
Facility City State ZIP Site status
Aptinyx Clinical Site Tuscaloosa Alabama 35404 —
Aptinyx Clinical Site Phoenix Arizona 85012 —
Aptinyx Clinical Site Bentonville Arkansas 72712 —
Aptinyx Clinical Site Bellflower California 90706 —
Aptinyx Clinical Site Glendale California 91206 —
Aptinyx Clinical Site La Jolla California 92037 —
Aptinyx Clinical Site Oceanside California 92056 —
Aptinyx Clinical Site Riverside California 92506 —
Aptinyx Clinical Site Santa Ana California 92705 —
Aptinyx Clinical Site Temecula California 92591 —
Aptinyx Clinical Site Torrance California 90502 —
Aptinyx Clinical Site Colorado Springs Colorado 80910 —
Aptinyx Clinical Site Denver Colorado 80209 —
Aptinyx Clinical Site Hialeah Florida 33012 —
Aptinyx Clinical Site Hollywood Florida 33020 —
Aptinyx Clinical Site Jacksonville Florida 32256 —
Aptinyx Clinical Site Jupiter Florida 33458 —
Aptinyx Clinical Site Miami Florida 33125 —
Aptinyx Clinical Site Miami Florida 33174 —
Aptinyx Clinical Site Miami Lakes Florida 33014 —
Aptinyx Clinical Site Okeechobee Florida 34972 —
Aptinyx Clinical Site Orlando Florida 32801 —
Aptinyx Clinical Site Atlanta Georgia 30331 —
Aptinyx Clinical Site Boston Massachusetts 02131 —
Aptinyx Clinical Site Las Vegas Nevada 89102 —
Aptinyx Clinical Site Albuquerque New Mexico 87102 —
Aptinyx Clinical Site New York New York 10036 —
Aptinyx Clinical Site Cincinnati Ohio 45219 —
Aptinyx Clinical Site Dayton Ohio 45432 —
Aptinyx Clinical Site Kettering Ohio 45439 —
Aptinyx Clinical Site North Canton Ohio 44720 —
Aptinyx Clinical Site Media Pennsylvania 19063 —
Aptinyx Clinical Site Memphis Tennessee 38119 —
Aptinyx Clinical Site Austin Texas 78737 —
Aptinyx Clinical Site Fort Worth Texas 76104 —
Aptinyx Clinical Site Houston Texas 77090 —
Aptinyx Clinical Site Plano Texas 75093 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05181995, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 7, 2023 · Synced Oct 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05181995 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →